When: June 3, 2020
Where: Anywhere you are!
Who: Ali Urman, Analyst, ARK Invest
In the first episode of the Emerge ARK ETF Innovation Series we sat down (virtually) with Ali Urman, Genomics Analyst, ARK Invest to discuss the Genomic Revolution.
Genomic Revolution Episode Highlights:
- DNA Sequencing costs declining; mapping of the human Genome
- ARK’s view of Covid-19
- Key Holdings Review: CRISPR, Arcturus Therapeutics Holdings Inc.
Ali Urman, Genomics Analyst, ARK Invest
Alexandra “Ali” joined ARK as an Analyst on the Genomic Revolution strategy in February 2020. She focuses on gene editing, stem cell and novel immunotherapy technologies.
Prior to ARK, Ali conducted clinical cancer research at the Memorial Sloan Kettering Cancer Center and the Montefiore Medical Center; and was a Senior Research Program Manager at IBM Watson Health. Ali incorporated her own consulting firm in 2018. Ali has a Bachelor of Arts from McGill University and a Masters in Epidemiology and Community Health from New York Medical College. She has additional training from the MIT Labs in Human-Computer Interaction for User Experience Design.
Ali has published over 25 articles spanning cancer research, AI and space medicine. She has three filed patents and received the Manager’s Choice Award in 2017 and 2018, and the Rookie of the Year Award in 2017 from IBM Watson Health.